{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:52:08Z","timestamp":1791388328415,"version":"4.3.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As the role of transarterial radioembolization (TARE) in resectable hepatocellular carcinoma (HCC) beyond Milan criteria remains undefined, this study compared preoperative TARE and chemoembolization (TACE) with primary resection to establish the optimal management strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed HCC patients who did not meet the Milan criteria and underwent primary liver resection, preoperative TACE, or preoperative TARE. Overall survival (OS), time to recurrence (TTR), and recurrence-free survival (RFS) were analyzed using Kaplan\u2013Meier estimates and Cox regression with inverse probability of treatment weighting (IPTW).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 226 patients were included (primary resection,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009127; preoperative TACE,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952; preoperative TARE,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947), with a median follow-up of 37.2 months. After IPTW, baseline characteristics were well balanced. Median OS was not reached in the primary resection and preoperative TARE, but was 60.7 months in the preoperative TACE group. Compared with primary resection, preoperative TACE was associated with worse OS (adjusted HR [aHR]: 2.72; 95% confidence interval [CI] 1.39\u20135.33;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), whereas OS with preoperative TARE was comparable (aHR: 1.14; 95% CI: 0.50\u20132.55;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.76) after IPTW. Similarly, TTR and RFS were significantly worse in the preoperative TACE (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), whereas no significant differences were observed between the preoperative TARE and primary liver resection groups after IPTW (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.59 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.57).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preoperative TARE showed no significant difference in survival from primary liver resection in resectable HCC beyond the Milan criteria and may serve as a reasonable alternative strategy when upfront surgery is not feasible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Optimal treatment for resectable hepatocellular carcinoma (HCC) beyond the Milan criteria is controversial. The role of preoperative transarterial radioembolization (TARE) compared with chemoembolization (TACE) or upfront resection remains unclear<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Preoperative TARE achieved survival outcomes comparable to primary resection, whereas preoperative TACE was associated with significantly inferior overall and recurrence-free survival<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Preoperative TARE demonstrates survival outcomes comparable to primary resection. It serves as a reasonable therapeutic alternative for resectable hepatocellular carcinoma beyond the Milan criteria, offering effective local control when immediate surgery is not feasible<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-026-12920-x","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:02Z","timestamp":1791385202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative radioembolization versus chemoembolization and upfront resection for resectable hepatocellular carcinoma beyond the Milan criteria"],"prefix":"10.1007","author":[{"given":"Jeayeon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyung Sun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Haeng","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Young","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Kyun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoungRok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Suk","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Wook","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9141-7773","authenticated-orcid":false,"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"12920_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M et al (2025) EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol 82:315\u2013374","journal-title":"J Hepatol"},{"key":"12920_CR2","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M et al (2023) AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78:1922\u20131965","journal-title":"Hepatology"},{"key":"12920_CR3","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V et al (2025) Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol 31:S228\u2013S254","journal-title":"Clin Mol Hepatol"},{"key":"12920_CR4","doi-asserted-by":"crossref","unstructured":"Kudo M, Han KH, Ye SL et al (2020) A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements. Liver Cancer 9:245\u2013260","DOI":"10.1159\/000507370"},{"key":"12920_CR5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3350\/cmh.2025.0724","volume":"31","author":"IC Lee","year":"2025","unstructured":"Lee IC, Wang HW, Teng W et al (2025) Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma. Clin Mol Hepatol 31:1213\u20131232","journal-title":"Clin Mol Hepatol"},{"key":"12920_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","volume":"56","author":"B Sangro","year":"2012","unstructured":"Sangro B, Inarrairaegui M, Bilbao JI (2012) Radioembolization for hepatocellular carcinoma. J Hepatol 56:464\u2013473","journal-title":"J Hepatol"},{"key":"12920_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G et al (2022) Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol 7:843\u2013850","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12920_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L et al (2022) 90Y Radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology 303:699\u2013710","journal-title":"Radiology"},{"key":"12920_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","volume":"84","author":"M Reig","year":"2025","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A et al (2025) BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update. J Hepatol 84:631\u2013654. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020","journal-title":"J Hepatol"},{"key":"12920_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","volume":"61","author":"L Yin","year":"2014","unstructured":"Yin L, Li H, Li AJ et al (2014) Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 61:82\u201388","journal-title":"J Hepatol"},{"key":"12920_CR11","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea practice guidelines for the management of hepatocellular carcinoma. J Liver Cancer 23:1\u2013120"},{"key":"12920_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3350\/cmh.2017.0004","volume":"23","author":"HC Kim","year":"2017","unstructured":"Kim HC (2017) Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol 23:109\u2013114","journal-title":"Clin Mol Hepatol"},{"key":"12920_CR13","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1148\/rg.2021210014","volume":"41","author":"FH Miller","year":"2021","unstructured":"Miller FH, Lopes Vendrami C, Gabr A et al (2021) Evolution of radioembolization in treatment of hepatocellular carcinoma: a pictorial review. Radiographics 41:1802\u20131818","journal-title":"Radiographics"},{"key":"12920_CR14","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220076","volume":"43","author":"HC Kim","year":"2023","unstructured":"Kim HC, Miyayama S, Choi JW, Kim GM, Chung JW (2023) Hepatocellular carcinoma supplied by the inferior phrenic artery or cystic artery: anatomic and technical considerations. Radiographics 43:e220076","journal-title":"Radiographics"},{"key":"12920_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1148\/rg.2019180110","volume":"39","author":"HC Kim","year":"2019","unstructured":"Kim HC, Miyayama S, Chung JW (2019) Selective chemoembolization of caudate lobe hepatocellular carcinoma: anatomy and procedural techniques. Radiographics 39:289\u2013302","journal-title":"Radiographics"},{"key":"12920_CR16","doi-asserted-by":"crossref","unstructured":"Miyayama S (2019) Ultraselective conventional transarterial chemoembolization: When and how? Clin Mol Hepatol 25:344\u2013353","DOI":"10.3350\/cmh.2019.0016"},{"key":"12920_CR17","doi-asserted-by":"crossref","unstructured":"Strasberg S, Belghiti J, Clavien P-A et al (2000) The Brisbane 2000 terminology of liver anatomy and resections.\u00a0HBP (Oxford) 2:333\u2013339","DOI":"10.1016\/S1365-182X(17)30755-4"},{"key":"12920_CR18","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:3661\u20133679","journal-title":"Stat Med"},{"key":"12920_CR19","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin PC (2016) Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med 35:5642\u20135655","journal-title":"Stat Med"},{"key":"12920_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35\u201343","journal-title":"Lancet Oncol"},{"key":"12920_CR21","doi-asserted-by":"crossref","unstructured":"Mazzaferro V, Bhoori S, Sposito C et al (2011) Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 17:S44\u2013S57","DOI":"10.1002\/lt.22365"},{"key":"12920_CR22","first-page":"1117","volume":"15","author":"J Nagashima","year":"1999","unstructured":"Nagashima J, Okuda K, Tanaka M, Sata M, Aoyagi S (1999) Prognostic benefit in cytoreductive surgery for curatively unresectable hepatocellular carcinoma\u2014comparison to transcatheter arterial chemoembolization. Int J Oncol 15:1117\u20131123","journal-title":"Int J Oncol"},{"key":"12920_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103:914\u2013921","journal-title":"Am J Gastroenterol"},{"key":"12920_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14740\/jocmr2496w","volume":"8","author":"K Liu","year":"2016","unstructured":"Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM (2016) The changes of HIF-1alpha and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res 8:297\u2013302","journal-title":"J Clin Med Res"},{"key":"12920_CR25","doi-asserted-by":"crossref","unstructured":"Pinto E, Pelizzaro F, Cardin R et al (2024) HIF-1\u03b1 and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization. Dig Liver Dis 56:872\u2013879","DOI":"10.1016\/j.dld.2023.09.019"},{"key":"12920_CR26","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1111\/j.1349-7006.2008.00909.x","volume":"99","author":"JH Shim","year":"2008","unstructured":"Shim JH, Park JW, Kim JH et al (2008) Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99:2037\u20132044","journal-title":"Cancer Sci"},{"key":"12920_CR27","doi-asserted-by":"crossref","unstructured":"Virmani S, Rhee TK, Ryu RK et al (2008) Comparison of hypoxia-inducible factor-1\u03b1 expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol 19:1483\u20131489","DOI":"10.1016\/j.jvir.2008.06.017"},{"key":"12920_CR28","doi-asserted-by":"crossref","unstructured":"Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497\u2013507.e2","DOI":"10.1053\/j.gastro.2010.10.049"},{"key":"12920_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/SLA.0b013e31821ad884","volume":"254","author":"K-C Lim","year":"2011","unstructured":"Lim K-C, Chow PK-H, Allen JC et al (2011) Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 254:108\u2013113","journal-title":"Ann Surg"},{"key":"12920_CR30","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1245\/s10434-008-9846-9","volume":"15","author":"S Sumie","year":"2008","unstructured":"Sumie S, Kuromatsu R, Okuda K et al (2008) Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 15:1375\u20131382","journal-title":"Ann Surg Oncol"},{"key":"12920_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9567041","volume":"2022","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, Guan R, Jianxi W et al (2022) Microvascular invasion in hepatocellular carcinoma: a review of its definition, clinical significance, and comprehensive management. J Oncol 2022:9567041","journal-title":"J Oncol"},{"key":"12920_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/archsurg.136.5.528","volume":"136","author":"MM Bilimoria","year":"2001","unstructured":"Bilimoria MM, Lauwers GY, Doherty DA et al (2001) Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 136:528\u2013535","journal-title":"Arch Surg"},{"key":"12920_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","volume":"68","author":"V Chew","year":"2019","unstructured":"Chew V, Lee YH, Pan L et al (2019) Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 68:335\u2013346","journal-title":"Gut"},{"key":"12920_CR34","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1245\/s10434-009-0454-0","volume":"16","author":"RC Gaba","year":"2009","unstructured":"Gaba RC, Lewandowski RJ, Kulik LM et al (2009) Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 16:1587\u20131596","journal-title":"Ann Surg Oncol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12920-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12920-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12920-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:06Z","timestamp":1791385206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12920-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":34,"alternative-id":["12920"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12920-x","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Yoon Jun Kim.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"One of the authors has significant statistical expertise.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was obtained (IRB No. E-2507-162-1659).","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap.","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}